298 related articles for article (PubMed ID: 35123927)
61. Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?
Atilla E; Atilla PA; Demirer T
Int J Hematol; 2017 Mar; 105(3):257-264. PubMed ID: 27995456
[TBL] [Abstract][Full Text] [Related]
62. SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024.
Ip A; Della Pia A; Goy AH
Clin Lymphoma Myeloma Leuk; 2024 Feb; ():. PubMed ID: 38493059
[TBL] [Abstract][Full Text] [Related]
63. Ibrutinib for mantle cell lymphoma.
Tucker DL; Rule SA
Future Oncol; 2016 Feb; 12(4):477-91. PubMed ID: 26759179
[TBL] [Abstract][Full Text] [Related]
64. Treatment options for mantle cell lymphoma.
Smolewski P; Witkowska M; Robak T
Expert Opin Pharmacother; 2015; 16(16):2497-507. PubMed ID: 26360791
[TBL] [Abstract][Full Text] [Related]
65. Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.
Puvvada SD; Guillen-Rodriguez J; Kumar A; Inclán L; Heard K; Rivera XI; Anwer F; Schatz JH; Mahadevan D; Persky DO
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):58-64. PubMed ID: 29056470
[TBL] [Abstract][Full Text] [Related]
66. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
[TBL] [Abstract][Full Text] [Related]
67. Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma.
Mussetti A; Kumar A; Dahi PB; Perales MA; Sauter CS
Blood Rev; 2015 May; 29(3):143-52. PubMed ID: 25468719
[TBL] [Abstract][Full Text] [Related]
68. Real-World Evidence of Relapsed/Refractory Mantle Cell Lymphoma Patients and Treatments: A Systematic Review.
Sancho JM; Sorigué M; Rubio-Azpeitia E
J Blood Med; 2024; 15():239-254. PubMed ID: 38812568
[TBL] [Abstract][Full Text] [Related]
69. Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience.
Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
Cancer Med; 2019 Nov; 8(16):6860-6870. PubMed ID: 31560165
[TBL] [Abstract][Full Text] [Related]
70. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
[TBL] [Abstract][Full Text] [Related]
71. Novel agents in mantle cell lymphoma.
Kumar A
Curr Oncol Rep; 2015 Aug; 17(8):34. PubMed ID: 26045130
[TBL] [Abstract][Full Text] [Related]
72. CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma.
Mohty R; Kharfan-Dabaja MA
Ther Adv Hematol; 2022; 13():20406207221142133. PubMed ID: 36544864
[TBL] [Abstract][Full Text] [Related]
73. Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
Bond DA; Alinari L; Maddocks K
Clin Adv Hematol Oncol; 2019 Apr; 17(4):223-233. PubMed ID: 31188814
[TBL] [Abstract][Full Text] [Related]
74. Recent advances in genomics and therapeutics in mantle cell lymphoma.
Lu T; Zhang J; McCracken JM; Young KH
Cancer Treat Rev; 2024 Jan; 122():102651. PubMed ID: 37976759
[TBL] [Abstract][Full Text] [Related]
75. Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy.
Girard J; Reneau J; Devata S; Wilcox RA; Kaminski MS; Mercer J; Carty S; Phillips TJ
Onco Targets Ther; 2019; 12():8003-8014. PubMed ID: 31686856
[TBL] [Abstract][Full Text] [Related]
76. Mantle cell lymphoma management trends and novel agents: where are we going?
Pu JJ; Savani M; Huang N; Epner EM
Ther Adv Hematol; 2022; 13():20406207221080743. PubMed ID: 35237397
[TBL] [Abstract][Full Text] [Related]
77. Mantle cell lymphoma: insights into therapeutic targets at the preclinical level.
Klener P
Expert Opin Ther Targets; 2020 Oct; 24(10):1029-1045. PubMed ID: 32842810
[TBL] [Abstract][Full Text] [Related]
78. Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
Novak U; Fehr M; Schär S; Dreyling M; Schmidt C; Derenzini E; Zander T; Hess G; Mey U; Ferrero S; Mach N; Boccomini C; Böttcher S; Voegeli M; Cairoli A; Ivanova VS; Menter T; Dirnhofer S; Scheibe B; Gadient S; Eckhardt K; Zucca E; Driessen C; Renner C
EClinicalMedicine; 2023 Oct; 64():102221. PubMed ID: 37781158
[TBL] [Abstract][Full Text] [Related]
79. The current therapeutic scenario for relapsed mantle cell lymphoma.
Ferrero S; Dreyling M
Curr Opin Oncol; 2013 Sep; 25(5):452-62. PubMed ID: 23872784
[TBL] [Abstract][Full Text] [Related]
80. Current and emerging therapies in mantle cell lymphoma.
Brett LK; Williams ME
Curr Treat Options Oncol; 2013 Jun; 14(2):198-211. PubMed ID: 23512567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
